imipenem, anhydrous has been researched along with Disease Models, Animal in 113 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (6.19) | 18.7374 |
| 1990's | 23 (20.35) | 18.2507 |
| 2000's | 38 (33.63) | 29.6817 |
| 2010's | 39 (34.51) | 24.3611 |
| 2020's | 6 (5.31) | 2.80 |
| Authors | Studies |
|---|---|
| Borrell, N; Maciá, MD; Moya, B; Oliver, A; Pérez, JL; Plasencia, V | 1 |
| Bonomo, RA; Endimiani, A; Hujer, AM; Hujer, KM; Pulse, ME; Weiss, WJ | 1 |
| Braisted, J; Dranchak, P; Earnest, TW; Gu, X; Hoon, MA; Inglese, J; Oliphant, E; Solinski, HJ | 1 |
| Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV | 1 |
| Al-Madboly, LA | 1 |
| Bozali, K; Cakir, A; Celikten, M; Durdu, B; Guler, EM; Kocyigit, A; Sahan, E; Sumbul, B | 1 |
| Fu, L; Li, H; Li, X; Liu, J; Luo, S; Wan, Z; Wang, Y; Wu, X; Xie, X; Zhao, Z | 1 |
| Canovas, J; Chau, F; Fantin, B; Le Monnier, A; Lefort, A; Petitjean, G | 1 |
| Ghaffari Khaligh, S; Hashemi, SM; Khosrojerdi, A; Soudi, S; Zavaran Hosseini, A | 1 |
| Bickler, SW; Cauvi, DM; Coimbra, R; De Maio, A; Escobedo, O; Halbach, JL; Hawisher, D; Lizardo, RE; Reyes, T; Rosas, J; Wang, AW | 1 |
| Kramer, J; Proschak, A; Proschak, E; Wichelhaus, TA | 1 |
| Bar-David, E; Ben-Shmuel, A; Brosh, T; Glinert, I; Kobiler, D; Levy, H; Schlomovitz, J; Sittner, A; Weiss, S | 1 |
| Giamarellos-Bourboulis, EJ; Kraniotaki, E; Perivolioti, E; Poulakou, G; Renieris, G; Sabrakos, L; Themeli-Digalaki, K; Zarkotou, O; Zavras, N | 1 |
| Agudelo, M; Rodriguez, CA; Vesga, O; Zuluaga, AF | 1 |
| Jiang, C; Liu, L; Liu, N; Xie, N; Xu, Y; Zhang, G | 1 |
| Chen, W; Harris, G; Kanzaki, G; Kuo Lee, R; Lam, CK; Patel, GB; Xu, HH | 1 |
| Ahmed, SS; Alp, E; Demiraslan, H; Dinc, G; Doganay, M; Elmali, F; Metan, G | 1 |
| Cirioni, O; Ghiselli, R; Giacometti, A; Guerrieri, M; Kamysz, E; Kamysz, W; Mazzocato, S; Offidani, A; Orlando, F; Provinciali, M; Silvestri, C; Simonetti, O | 1 |
| Chen, JC; Chen, JY; Lin, TL; Pan, CY; Sheen, JF | 1 |
| Boutoille, D; Bretonnière, C; Caillon, J; Desessard, C; Guitton, C; Jacqueline, C; Potel, G | 1 |
| Bellevue, O; Brown, I; Harris, HW; Kasravi, S; Lee, M; Lyo, V; Rayikanti, B; Shawo, A; Uzosike, ED; Woldesemayat, H | 1 |
| Mangin, E; Mavridou, E; Melchers, RJ; Motyl, MR; Mouton, JW; van Mil, AC | 1 |
| Chau, F; Couffignal, C; Fantin, B; Lepeule, R; Massias, L; Mentre, F; Rossi, B; Ruppé, E; Soubirou, JF | 1 |
| Choudhury, S; Darzi, SA; Dash, JR; Debroy, B; Kannan, K; Mishra, SK; Parida, S; Paul, A; Pule Addison, M; Singh, TU; Singh, V; Thangamalai, R | 1 |
| Altboum, Z; Bar-David, E; Glinert, I; Kobiler, D; Levy, H; Schlomovitz, J; Sittner, A; Weiss, S | 1 |
| Chau, F; Dion, S; Fantin, B; Lefort, A; Lepeule, R; Massias, L; Rossi, B; Soubirou, JF | 1 |
| Saito, H; Starr, ME; Steele, AM | 1 |
| Aranda, F; Armiger-Borràs, N; Carrasco, E; Consuegra-Fernández, M; Di Scala, M; González-Aseguinolaza, G; Lozano, F; Martínez-Florensa, M; Pachón, J; Vila, J | 1 |
| Chen, ZL; Liu, SW; Wu, WK; Xu, J; Xu, XY; Yuan, JY; Zhang, N | 1 |
| Morrison, DC; Papasian, CJ; Qureshi, AA; Qureshi, N; Reis, J; Rockwell, CE; Tan, X; Vogel, SN; Yang, R | 1 |
| Cheong, HJ; Kim, WJ; Lee, J; Song, JY; Sung, AK | 1 |
| Chen, XG; Jiang, WL; Tian, JW; Zhu, HB | 1 |
| Chen, XG; Fu, FH; Jiang, WL; Qu, GW; Tian, JW; Yue, XD; Zhu, HB | 1 |
| Docobo-Perez, F; Garcia-Curiel, A; Jiménez-Mejías, ME; López-Rojas, R; Pachon, J; Pachón-Ibañez, ME; Pichardo, C | 1 |
| Ariza, J; Cabellos, C; Domínguez, MA; Fernández, R; Gudiol, F; Pachón-Ibáñez, ME; Ribes, S; Tubau, F | 2 |
| Bonomo, RA; Cassone, M; Harmos, F; Hoffmann, R; Knappe, D; Kovalszky, I; Ostorhazi, E; Otvos, L; Rozgonyi, F; Szabo, D; Sztodola, A; Wade, JD | 1 |
| Boutoille, D; Bretonnière, C; Caillon, J; Guitton, C; Jacqueline, C; Le Mabecque, V; Miégeville, AF; Potel, G; Villers, D | 1 |
| Conejo, MC; Docobo-Pérez, F; García, I; López-Rojas, R; Pachón, J; Pachón-Ibáñez, ME; Pascual, A; Pichardo, C; Rodríguez, JM; Velasco, C | 1 |
| Abbanat, D; Barron, A; Bunting, RA; Fernandez, J; Flamm, RK; Hall, L; Hilliard, JJ; Lynch, AS; Melton, JL; Ward, CK | 1 |
| Docobo-Pérez, F; García-Curiel, A; Ibáñez-Martínez, J; Jiménez-Mejias, ME; Pachón, J; Pachón-Ibáñez, ME; Pichardo, C | 1 |
| Tuğrul, HM; Yıldırım, MI | 1 |
| Hou, J; Jiang, WL; Xu, Y; Zhang, SP; Zhu, HB | 1 |
| Chen, CC; Chen, CH; Chiang, SR; Chuang, YC; Ko, WC; Lee, NY; Shieh, JM; Tang, HJ | 1 |
| Boutoille, D; Bretonnière, C; Caillon, J; Desessard, C; Guitton, C; Jacqueline, C; Le Mabecque, V; Miégeville, AF; Potel, G; Villers, D | 1 |
| Chau, F; Fantin, B; Le, P; Lefort, A; Lepeule, R; Massias, L; Nucci, A; Ruppé, E | 1 |
| Ciofu, O; Hengzhuang, W; Høiby, N; Song, Z; Wu, H | 1 |
| Baryshnikova, A; Benton-Perdomo, L; Caron, A; Claveau, D; Daigneault, E; Deschamps, K; Elsen, NL; Gill, CJ; Kramer, S; Landry, F; Langlois, E; Lebeau-Jacob, C; Lee, SH; Liang, L; Lu, J; Lumb, KJ; Maxwell, E; Meredith, TC; Monteiro, JM; Parthasarathy, G; Pereira, PM; Petcu, M; Pinho, MG; Ramtohul, Y; Reid, JC; Roemer, T; Sharma, S; Sillaots, S; Skorey, K; Soisson, SM; Tam, J; Tan, CM; Therien, AG; Vaillancourt, J; Wang, H; Wang-Jarantow, L; Wong, S; Wu, J | 1 |
| Ariza, J; Cabellos, C; Cabo, J; Garrigós, C; Lora-Tamayo, J; Murillo, O; Tubau, F; Verdaguer, R | 1 |
| Harada, S; Ishii, Y; Kimura, S; Livermore, DM; Saga, T; Tateda, K; Woodford, N; Yamaguchi, K; Yoshizumi, A | 1 |
| Cirioni, O; Ghiselli, R; Giacometti, A; Mocchegiani, F; Saba, V; Scalise, G; Viticchi, C | 1 |
| Amiot, DM; Buchman, TG; Coopersmith, CM; Davis, CG; Dunne, WM; Hotchkiss, RS; Husain, KD; Karl, IE; Osborne, DF; Stromberg, PE; Turnbull, IR | 1 |
| Engelbert, M; Grasbon, T; Kampik, A; Klauss, V; Mette, M; Miño de Kaspar, H; Schulze-Schwering, M; Ta, CN; Thiel, M | 1 |
| Amâncio, RT; Bozza, FA; Bozza, PT; Castro-Faria-Neto, HC; David, CM; Gomes, RN; Vianna, RC | 1 |
| Engelbert, M; Grasbon, T; Kampik, A; Klauss, V; Miño de Kaspar, H; Schulze-Schwering, M; Ta, CN; Thiel, M | 1 |
| Stanojlovic, O; Stojanovic, J; Susic, V; Zivanovic, D | 1 |
| Cirioni, O; D'Amato, G; Ghiselli, R; Giacometti, A; Kamysz, W; Lukasiak, J; Mocchegiani, F; Orlando, F; Saba, V; Scalise, G; Silvestri, C | 1 |
| Bugnon, D; Caillon, J; Gras-Le Guen, C; Jacqueline, C; Kergueris, MF; Navas, D; Potel, G | 1 |
| Balaban, N; Cirioni, O; D'Amato, G; Del Prete, MS; Dell'Acqua, G; Ghiselli, R; Giacometti, A; Mocchegiani, F; Orlando, F; Rocchi, M; Saba, V; Scalise, G; Silvestri, C | 1 |
| Bernabeu-Wittel, M; García-Curiel, A; Ibáñez-Martínez, J; Jiménez-Mejías, ME; Pachón, J; Pachón-Ibáñez, ME; Pichardo, C | 1 |
| Chambers, HF; Hopewell, PC; Kawamura, M; Schecter, GF; Turner, J | 1 |
| Conejo, C; Ibáñez-Martínez, J; Martínez-Martínez, L; Pachón, J; Pachón-Ibañez, ME; Pascual, A; Pichardo, C; Rodríguez-Martínez, JM | 1 |
| Cirioni, O; Ghiselli, R; Giacometti, A; Kamysz, W; Licci, A; Mocchegiani, F; Orlando, F; Saba, V; Scalise, G; Silvestri, C; Łukasiak, J | 1 |
| Aydin, K; Aydin, S; Caylan, R; Koksal, I; Yenilmez, E; Yulug, E | 1 |
| Ding, L; Gong, J; Hu, B; Hu, J; Li, QQ; Liu, S; Reed, E; Sun, Z; Wang, J; Xu, M; Yan, Q; Zhu, X | 1 |
| Bergnach, C; Cirioni, O; Ghiselli, R; Giacometti, A; Licci, A; Mocchegiani, F; Orlando, F; Rocchi, M; Saba, V; Scalise, G; Silvestri, C; Skerlavaj, B; Zanetti, M | 1 |
| Barnea, Y; Carmeli, Y; Dagan, S; Eren, R; Gat, A; Gur, E; Kuzmenko, B; Navon-Venezia, S; Neville, LF | 1 |
| Barra, D; Bozzi, A; Cirioni, O; Di Giulio, A; Ghiselli, R; Giacometti, A; Luzi, C; Mangoni, ML; Mocchegiani, F; Orlando, F; Rinaldi, AC; Saba, V; Scalise, G; Silvestri, C | 1 |
| Docobo-Pérez, F; Fernández-Cuenca, F; Pachón, J; Pachón-Ibáñez, ME; Pascual, A | 1 |
| Gómez Gómez, J; López Fornás, F; Lorente Salinas, I; Martínez García, F; Pérez Salmerón, J; Roldán Conesa, D; Ruiz Gómez, J; Segovia Hernández, M; Valdés Chávarri, M | 1 |
| Beger, HG; Gansauge, F; Isenmann, R; Kriese, D; Poch, B; Rozdzinski, E; Schwarz, M | 1 |
| Katsube, T; Yamano, Y; Yano, Y | 1 |
| De Kaspar, HM; Engelbert, M; Kampik, A; Mette, M; Ta, CN; Thiel, M | 1 |
| Brzoska, T; Klehmet, J; Meisel, A; Meisel, C; Quarcoo, D; Schulte-Herbrüggen, O | 1 |
| Hikida, M; Ito, F; Kataoka, H; Kijima, K; Maebashi, K; Mikami, Y; Muto, Y; Niida, M; Sakakibara, S; Shimizu, A; Suzuki, K; Takata, T; Takeda, K; Unno, M | 1 |
| Edelstein, PH | 1 |
| Bucklin, SE; Lake, P; Lögdberg, L; Morrison, DC | 1 |
| Lahnborg, G; Nord, CE | 1 |
| Fernández-del Castillo, C; Ferraro, MJ; Foitzik, T; Mithöfer, K; Rattner, DW; Warshaw, AL | 1 |
| Bucklin, SE; Fujihara, Y; Leeson, MC; Morrison, DC | 1 |
| Garcia, A; Martín-Luengo, F; Martínez, F; Valdés, M | 1 |
| Munakata, K; Satoh, M; Takeuchi, H; Yoshida, O | 1 |
| Andremont, A; Carbon, C; Massias, L; Montravers, P | 1 |
| Anderson, LH; Mehm, WJ; Muhvich, KH | 1 |
| Asahi, Y; Goto, M; Inoue, M; Kaji, Y; Kimura, S; Matsuda, K; Nakagawa, S; Oka, S; Sanada, M; Shimada, K | 1 |
| Dalhoff, A; Nitsche, D; Oesser, S; Sack, M; Schulze, C | 1 |
| Hatori, T; Matsumoto, T; Miyazaki, H; Takashima, K; Tateda, K; Yamaguchi, K | 1 |
| Alfaro, DV; Bevin, AA; Hudson, SJ; Laughlin, RM; Mines, M; offele, JJ; Schoderbek, RJ | 1 |
| Alfaro, DV; Barton, CP; Beverly, DT; Brucker, AJ; Hudson, SJ; Kasowski, EJ; King, LP; Lopez, JD | 1 |
| D'Amico, DT; Ng, EW | 1 |
| Battles, A; Liu, QF; Liu, W; Louie, A; Miller, DA; Miller, MH; Sucke, AC | 1 |
| Desaty, TM; Griffin, TJ; Heifetz, CL; Sesnie, JC; Shapiro, MA | 1 |
| Hogaboam, CM; Kunkel, SL; Lukacs, NW; Steinhauser, ML; Strieter, RM | 1 |
| Elhelali, N; Jacolot, A; Laurent, F; Léotard, S; Mimoz, O; Nordmann, P; Petitjean, O; Samii, K | 1 |
| Ernst, EJ; Guglielmo, J; Hashimoto, S; Jackson, JJ; Kropp, H; Pittet, JF; Sawa, T; Wiener-Kronish, JP | 1 |
| Cristofori, P; Di Modugno, E; Ladel, CH; Lanzoni, A; Marzola, P; Nicolato, E; Sbarbati, A | 1 |
| Isaji, S; Takagi, K | 1 |
| Bryskier, A; Carbon, C; Farinotti, R; Joly-Guillou, ML; Wolff, M | 1 |
| Caballero, FJ; Cuberos, L; García-Curiel, A; Jiménez-Mejías, ME; Moreno, I; Pachón, J; Pichardo, C; Rodríguez-Hernández, MJ | 1 |
| Abe, T; Fukuoka, T; Inoue, H; Ohya, S | 1 |
| Akiyama, H; Arata, J; Toi, Y; Yamasaki, O | 1 |
| Cirioni, O; Ghiselli, R; Giacometti, A; Mocchegiani, F; Orlando, F; Pacci, AM; Saba, V; Scalise, G | 1 |
| Higashiyama, Y; Hirakata, Y; Kadota, JI; Kakeya, H; Kaneko, Y; Kohno, S; Kuroki, M; Miyazaki, Y; Ohi, H; Tomono, K; Yanagihara, K | 1 |
| Ağca, B; Kalyoncu, A; Mihmanli, A; Sahin, I; Sakiz, D; Tahaoğlu, K; Tuncer, F | 1 |
| Atkinson, AM; Teale, DM | 1 |
| Auvergnat, JC; Dabernat, H; Froidefond, S; Lemozy, J; Marchou, B; Saivin, S | 1 |
| Chambers, HF; Kennedy, S; Sachdeva, M | 1 |
| Calame, W; Craig, WA; Ebert, S; Fantin, B; Leggett, JE; Mattie, H; Totsuka, K; Vogelman, B | 1 |
| Brook, I | 1 |
| Traub, WH | 1 |
| Hessen, MT; Levison, ME; Pitsakis, PG | 1 |
| Bennett, DB; Comereski, CR; Williams, PD | 1 |
| Donabedian, H; Freimer, EH | 1 |
1 review(s) available for imipenem, anhydrous and Disease Models, Animal
| Article | Year |
|---|---|
Pathogenesis and treatment of endocarditis.
Topics: Animals; Cilastatin; Cyclopropanes; Disease Models, Animal; Endocarditis, Bacterial; Humans; Imipenem; Microbial Sensitivity Tests; Rabbits; Staphylococcal Infections; Thienamycins | 1985 |
112 other study(ies) available for imipenem, anhydrous and Disease Models, Animal
| Article | Year |
|---|---|
Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents.
Topics: Animals; Anti-Bacterial Agents; Ceftazidime; Ciprofloxacin; Disease Models, Animal; Drug Resistance, Microbial; Drug Synergism; Drug Therapy, Combination; Female; Humans; In Vitro Techniques; Lung; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests; Mutation; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2007 |
Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae.
Topics: Animals; Anti-Bacterial Agents; Azabicyclo Compounds; Ceftazidime; Disease Models, Animal; Female; Klebsiella Infections; Klebsiella pneumoniae; Mice; Microbial Sensitivity Tests; Sepsis | 2011 |
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, Spinal; Humans; Mice, Inbred C57BL; Mice, Knockout; Neurons; Pruritus; Receptors, Atrial Natriuretic Factor; Reproducibility of Results; Signal Transduction; Small Molecule Libraries | 2019 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection | 2020 |
A Novel Triple Combination To Combat Serious Infections with Carbapenem-Resistant Acinetobacter baumannii in a Mouse Pneumonia Model.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Animals; Anti-Bacterial Agents; Ascorbic Acid; Biological Factors; Carbapenems; Disease Models, Animal; Drug Resistance, Multiple, Bacterial; Drug Synergism; Humans; Imipenem; Inflammation; Mice; Microbial Sensitivity Tests; Pneumonia; Transferrins | 2022 |
Examination of antimicrobial effect of fluoxetine in experimental sepsis model: An in vivo study.
Topics: Animals; Anti-Infective Agents; Antioxidants; C-Reactive Protein; Disease Models, Animal; Fluoxetine; Imipenem; Interleukin-6; Lactates; Oxidative Stress; Rats; Sepsis; Tumor Necrosis Factor-alpha | 2023 |
In vitro and in vivo assessment of the antibacterial activity of colistin alone and in combination with other antibiotics against Acinetobacter baumannii and Escherichia coli.
Topics: Acinetobacter baumannii; Administration, Intravenous; Animals; Anti-Bacterial Agents; Biofilms; Colistin; Disease Models, Animal; Doripenem; Drug Resistance, Multiple, Bacterial; Drug Synergism; Drug Therapy, Combination; Escherichia coli; Escherichia coli Infections; Female; Humans; Imipenem; Meropenem; Mice; Microbial Sensitivity Tests; Monte Carlo Method; Sulbactam; Treatment Outcome; Urinary Tract Infections | 2020 |
Expression of CTX-M-15 limits the efficacy of ceftolozane/tazobactam against Escherichia coli in a high-inoculum murine peritonitis model.
Topics: Animals; Anti-Bacterial Agents; Bacterial Load; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Cephalosporins; Disease Models, Animal; Escherichia coli; Escherichia coli Infections; Imipenem; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Peritonitis; Tazobactam | 2020 |
Imipenem alters systemic and liver inflammatory responses in CLP- induced sepsis mice in a dose-dependent manner.
Topics: Animals; Anti-Bacterial Agents; Bacterial Load; Cecum; Cytokines; Disease Models, Animal; Endotoxins; Female; Humans; Imipenem; Injections, Subcutaneous; Liver; Mice; Mice, Inbred C57BL; Sepsis | 2021 |
Why Antibiotic Treatment Is Not Enough for Sepsis Resolution: an Evaluation in an Experimental Animal Model.
Topics: Animals; Anti-Bacterial Agents; Disease Models, Animal; Imipenem; Mice; Sepsis; Survival Analysis; Treatment Outcome | 2017 |
Bacterial zincophore [S,S]-ethylenediamine-N,N'-disuccinic acid is an effective inhibitor of MBLs.
Topics: Animals; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Disease Models, Animal; Enzyme Inhibitors; Ethylenediamines; Gram-Negative Bacteria; Imipenem; Klebsiella Infections; Lepidoptera; Microbial Sensitivity Tests; Succinates; Survival Analysis; Treatment Outcome | 2018 |
Treating Anthrax-Induced Meningitis in Rabbits.
Topics: Animals; Anthrax; Anti-Bacterial Agents; Antitoxins; Bacillus anthracis; Central Nervous System; Ciprofloxacin; Clindamycin; Dexamethasone; Disease Models, Animal; Drug Combinations; Imipenem; Levofloxacin; Linezolid; Meningitis, Bacterial; Meropenem; Rabbits; Treatment Failure | 2018 |
Daptomycin as adjunctive treatment for experimental infection by Acinetobacter baumannii with resistance to colistin.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Animals; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Colistin; Daptomycin; Disease Models, Animal; Drug Resistance, Multiple, Bacterial; Drug Synergism; Drug Therapy, Combination; Humans; Imipenem; Male; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests | 2019 |
Nontherapeutic equivalence of a generic product of imipenem-cilastatin is caused more by chemical instability of the active pharmaceutical ingredient (imipenem) than by its substandard amount of cilastatin.
Topics: Animals; Bacteria; Bacterial Infections; Cilastatin; Cilastatin, Imipenem Drug Combination; Disease Models, Animal; Drug Stability; Drugs, Generic; Humans; Imipenem; Klebsiella pneumoniae; Mice; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Staphylococcus aureus; Therapeutic Equivalency | 2019 |
Treatment with andrographolide sulfonate provides additional benefits to imipenem in a mouse model of Klebsiella pneumoniae pneumonia.
Topics: Animals; Anti-Bacterial Agents; Bacterial Load; Cell Movement; Disease Models, Animal; Diterpenes; Humans; Imipenem; Inflammation; Klebsiella Infections; Klebsiella pneumoniae; Male; Mice, Inbred C57BL; Monocyte Chemoattractant Proteins; NLR Family, Pyrin Domain-Containing 3 Protein; Pneumonia; Survival Analysis; THP-1 Cells | 2019 |
A mouse model of Acinetobacter baumannii-associated pneumonia using a clinically isolated hypervirulent strain.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Animals; Anti-Bacterial Agents; Bacteremia; Bacterial Vaccines; Body Weight; Bronchopneumonia; Disease Models, Animal; Female; Imipenem; Immunization; Lung; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Microbial Sensitivity Tests; Minocycline; Pneumonia, Bacterial; Reproducibility of Results; Tigecycline; Time Factors | 2013 |
Efficacy of sulbactam and its combination with imipenem, colistin and tigecycline in an experimental model of carbapenem-resistant Acinetobacter baumannii sepsis.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Animals; Anti-Bacterial Agents; Bacterial Load; Carbapenems; Colistin; Disease Models, Animal; Drug Resistance, Bacterial; Drug Therapy, Combination; Humans; Imipenem; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Minocycline; Sepsis; Sulbactam; Tigecycline; Time Factors | 2013 |
In vitro activity and in vivo animal model efficacy of IB-367 alone and in combination with imipenem and colistin against Gram-negative bacteria.
Topics: Acinetobacter baumannii; Administration, Topical; Animals; Anti-Bacterial Agents; Antimicrobial Cationic Peptides; Colistin; Disease Models, Animal; Drug Therapy, Combination; Escherichia coli; Gram-Negative Bacterial Infections; Humans; Imipenem; Injections, Intraperitoneal; Klebsiella pneumoniae; Mice, Inbred BALB C; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 2014 |
Epinecidin-1 has immunomodulatory effects, facilitating its therapeutic use in a mouse model of Pseudomonas aeruginosa sepsis.
Topics: Amino Acid Sequence; Animals; Anti-Bacterial Agents; Antimicrobial Cationic Peptides; Behavior, Animal; Disease Models, Animal; Drug Resistance, Multiple, Bacterial; Fish Proteins; Humans; Imipenem; Immunologic Factors; Male; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests; Molecular Sequence Data; Pseudomonas aeruginosa; Pseudomonas Infections; Sepsis; Survival Analysis; Toxicity Tests, Acute | 2014 |
In vivo efficacy of ceftolozane against Pseudomonas aeruginosa in a rabbit experimental model of pneumonia: comparison with ceftazidime, piperacillin/tazobactam and imipenem.
Topics: Animal Structures; Animals; Anti-Bacterial Agents; Bacterial Load; Ceftazidime; Cephalosporins; Colony Count, Microbial; Disease Models, Animal; Female; Humans; Imipenem; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Treatment Outcome | 2014 |
Low-dose cyclophosphamide improves survival in a murine treatment model of sepsis.
Topics: Animals; Anti-Bacterial Agents; Bacteria; Cyclophosphamide; Disease Models, Animal; Imipenem; Immunosuppressive Agents; Lung; Macrophages, Peritoneal; Male; Mice; Mice, Inbred ICR; Peyer's Patches; Phagocytosis; Sepsis | 2015 |
Pharmacodynamics of imipenem in combination with β-lactamase inhibitor MK7655 in a murine thigh model.
Topics: Animals; beta-Lactamase Inhibitors; Disease Models, Animal; Female; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Mice; Pseudomonas aeruginosa; Pseudomonas Infections; Thigh | 2015 |
Activity of temocillin in a murine model of urinary tract infection due to Escherichia coli producing or not producing the ESBL CTX-M-15.
Topics: Animals; Anti-Bacterial Agents; beta-Lactamases; Disease Models, Animal; Escherichia coli; Escherichia coli Infections; Female; Imipenem; Mice, Inbred CBA; Microbial Sensitivity Tests; Penicillins; Treatment Outcome; Urinary Tract Infections | 2015 |
Combined treatment with atorvastatin and imipenem improves survival and vascular functions in mouse model of sepsis.
Topics: Animals; Anti-Bacterial Agents; Atorvastatin; Disease Models, Animal; Drug Therapy, Combination; Endothelium, Vascular; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imipenem; Male; Mice; Organ Culture Techniques; Sepsis; Survival Rate | 2015 |
Efficacy of Single and Combined Antibiotic Treatments of Anthrax in Rabbits.
Topics: Amoxicillin-Potassium Clavulanate Combination; Animals; Anthrax; Anti-Bacterial Agents; Bacillus anthracis; Bacteremia; Ciprofloxacin; Clarithromycin; Disease Models, Animal; Doxycycline; Drug Combinations; Drug Synergism; Humans; Imipenem; Linezolid; Male; Microbial Sensitivity Tests; Rabbits; Respiratory Tract Infections; Rifampin; Spores, Bacterial; Survival Analysis; Vancomycin | 2015 |
Cefotaxime and Amoxicillin-Clavulanate Synergism against Extended-Spectrum-β-Lactamase-Producing Escherichia coli in a Murine Model of Urinary Tract Infection.
Topics: Amoxicillin-Potassium Clavulanate Combination; Animals; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Cefotaxime; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Female; Gene Expression; Humans; Imipenem; Mice; Mice, Inbred CBA; Microbial Sensitivity Tests; Plasmids; Pyelonephritis; Urinary Tract Infections; Uropathogenic Escherichia coli | 2016 |
Late Therapeutic Intervention with Antibiotics and Fluid Resuscitation Allows for a Prolonged Disease Course with High Survival in a Severe Murine Model of Sepsis.
Topics: Animals; Anti-Bacterial Agents; Bacteremia; Cytokines; Disease Models, Animal; Fluid Therapy; Imipenem; Male; Mice; Mice, Inbred C57BL; Sepsis | 2017 |
Protective Effects of Human and Mouse Soluble Scavenger-Like CD6 Lymphocyte Receptor in a Lethal Model of Polymicrobial Sepsis.
Topics: Animals; Anti-Bacterial Agents; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Cecum; Cilastatin; Cilastatin, Imipenem Drug Combination; Cytokines; Dependovirus; Disease Models, Animal; Drug Combinations; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Imipenem; Ligation; Male; Mice; Mice, Inbred C57BL; Receptors, Scavenger; Sepsis | 2017 |
Multi-drug resistant uropathogenic Escherichia coli and its treatment by Chinese medicine.
Topics: Animals; Disease Models, Animal; Drug Resistance, Multiple, Bacterial; Drugs, Chinese Herbal; Escherichia coli Infections; Female; Imipenem; Mice, Inbred BALB C; Organ Specificity; Treatment Outcome; Uropathogenic Escherichia coli; Virulence | 2017 |
A combination of proteasome inhibitors and antibiotics prevents lethality in a septic shock model.
Topics: Animals; Anti-Bacterial Agents; Antioxidants; Cell Death; Cell Line; Cysteine Proteinase Inhibitors; Disease Models, Animal; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imipenem; Lipopolysaccharides; Lovastatin; Macrophages; Mice; Nitric Oxide; Proteasome Inhibitors; Quercetin; Shock, Septic; Tumor Necrosis Factor-alpha | 2008 |
Efficacy of monotherapy and combined antibiotic therapy for carbapenem-resistant Acinetobacter baumannii pneumonia in an immunosuppressed mouse model.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Animals; Anti-Bacterial Agents; Carbapenems; Colistin; Disease Models, Animal; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Humans; Imipenem; Immunosuppression Therapy; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Neutropenia; Pneumonia, Bacterial; Rifampin; Treatment Outcome | 2009 |
Effect of cornuside on experimental sepsis.
Topics: Animals; Anti-Bacterial Agents; Colony Count, Microbial; Cornus; Cytokines; Disease Models, Animal; Dose-Response Relationship, Drug; Down-Regulation; Drug Therapy, Combination; Endotoxins; Fruit; Glucosides; Imipenem; Immunologic Factors; Inflammation Mediators; Macrophages; Male; Myeloid Cells; Nitric Oxide; Peroxidase; Phytotherapy; Plant Extracts; Pyrans; Random Allocation; Rats; Rats, Sprague-Dawley; Sepsis; Up-Regulation | 2009 |
Rosmarinic acid protects against experimental sepsis by inhibiting proinflammatory factor release and ameliorating hemodynamics.
Topics: Animals; Anti-Bacterial Agents; Cinnamates; Depsides; Disease Models, Animal; Endotoxins; Gene Expression Regulation; Hemodynamics; Humans; Imipenem; Inflammation; Male; Mice; Myeloid Cells; Rats; Rats, Sprague-Dawley; Rosmarinic Acid; Sepsis; Tretinoin | 2009 |
Efficacy of tigecycline vs. imipenem in the treatment of experimental Acinetobacter baumannii murine pneumonia.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Animals; Anti-Bacterial Agents; Area Under Curve; Disease Models, Animal; Female; Imipenem; Lung; Mice; Mice, Inbred C57BL; Minocycline; Pneumonia, Bacterial; Statistics, Nonparametric; Tigecycline | 2010 |
In vitro and in vivo activities of linezolid alone and combined with vancomycin and imipenem against Staphylococcus aureus with reduced susceptibility to glycopeptides.
Topics: Acetamides; Animals; Ascitic Fluid; Bacteremia; Disease Models, Animal; Drug Resistance, Multiple, Bacterial; Drug Synergism; Drug Therapy, Combination; Glycopeptides; Imipenem; Linezolid; Methicillin Resistance; Methicillin-Resistant Staphylococcus aureus; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests; Oxazolidinones; Peritonitis; Staphylococcal Infections; Staphylococcus aureus; Vancomycin | 2010 |
Preclinical advantages of intramuscularly administered peptide A3-APO over existing therapies in Acinetobacter baumannii wound infections.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Animals; Anti-Bacterial Agents; Burns; Colistin; Disease Models, Animal; Female; Humans; Imipenem; Injections, Intramuscular; Mice; Peptides; Plasma; Treatment Outcome; Wound Infection | 2010 |
Efficacy of fosfomycin and its combination with linezolid, vancomycin and imipenem in an experimental peritonitis model caused by a Staphylococcus aureus strain with reduced susceptibility to vancomycin.
Topics: Acetamides; Animals; Anti-Bacterial Agents; Ascitic Fluid; Bacteremia; Bacterial Load; Disease Models, Animal; Drug Therapy, Combination; Female; Fosfomycin; Humans; Imipenem; Linezolid; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests; Oxazolidinones; Peritonitis; Staphylococcal Infections; Treatment Outcome; Vancomycin | 2011 |
Efficacy of doripenem in the treatment of Pseudomonas aeruginosa experimental pneumonia versus imipenem and meropenem.
Topics: Animals; Anti-Bacterial Agents; Bacterial Load; Blood; Carbapenems; Disease Models, Animal; Doripenem; Female; Imipenem; Infusions, Intravenous; Lung; Meropenem; Plasma; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Spleen; Thienamycins; Treatment Outcome | 2010 |
Local imipenem activity against Pseudomonas aeruginosa decreases in vivo in the presence of siliconized latex.
Topics: Animals; Anti-Bacterial Agents; Bacterial Load; Catheters; Disease Models, Animal; Drug Antagonism; Female; Foreign Bodies; Imipenem; Latex; Liver; Mice; Mice, Inbred C57BL; Peritonitis; Pseudomonas aeruginosa; Pseudomonas Infections; Silicon; Spleen; Treatment Outcome; Zinc | 2011 |
Comparative effects of carbapenems on bacterial load and host immune response in a Klebsiella pneumoniae murine pneumonia model.
Topics: Animals; Anti-Bacterial Agents; Bacterial Load; beta-Lactamases; Carbapenems; Cytokines; Disease Models, Animal; Doripenem; Female; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Lung; Meropenem; Mice; Mice, Inbred C3H; Microbial Sensitivity Tests; Pneumonia, Bacterial; Thienamycins; Treatment Outcome | 2011 |
Efficacy of rifampin, in monotherapy and in combinations, in an experimental murine pneumonia model caused by panresistant Acinetobacter baumannii strains.
Topics: Acinetobacter baumannii; Animals; Anti-Bacterial Agents; Bacterial Load; Disease Models, Animal; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Female; Imipenem; Lung; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests; Microbial Viability; Pneumonia, Bacterial; Rifampin; Rodent Diseases; Sulbactam; Treatment Outcome | 2011 |
[Assessment of efficacies of imipenem, cefoperazone-sulbactam and cefepime in rats with experimental thigh abscess model with multidrug resistant and susceptible Acinetobacter baumannii strains].
Topics: Abscess; Acinetobacter baumannii; Acinetobacter Infections; Animals; Anti-Bacterial Agents; Cefepime; Cefoperazone; Cephalosporins; Colony Count, Microbial; Disease Models, Animal; Drug Combinations; Drug Resistance, Multiple, Bacterial; Female; Imipenem; Random Allocation; Rats; Rats, Wistar; Serum Bactericidal Test; Soft Tissue Infections; Sulbactam; Thigh | 2011 |
Protocatechuic aldehyde protects against experimental sepsis in vitro and in vivo.
Topics: Animals; Anti-Bacterial Agents; Benzaldehydes; Catechols; Cell Line; Disease Models, Animal; Drug Therapy, Combination; HMGB1 Protein; Imipenem; Inflammation; Inflammation Mediators; Injections, Intravenous; Interleukin-10; Macrophages; Male; NF-kappa B; Phosphorylation; Rats; Rats, Sprague-Dawley; Sepsis; Tumor Necrosis Factor-alpha | 2012 |
Comparative evaluation of intratracheal colistimethate sodium, imipenem, and meropenem in BALB/c mice with carbapenem-resistant Acinetobacter baumannii pneumonia.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Acute Disease; Animals; Anti-Bacterial Agents; Carbapenems; Cilastatin; Cilastatin, Imipenem Drug Combination; Colistin; Cytokines; Disease Models, Animal; Drug Combinations; Drug Resistance, Bacterial; Female; Imipenem; Meropenem; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Pneumonia, Bacterial; Stem Cells; Thienamycins | 2012 |
Evaluation of doripenem in an experimental model of resistant Pseudomonas aeruginosa pneumonia.
Topics: Animals; Anti-Bacterial Agents; Bacterial Load; beta-Lactam Resistance; Carbapenems; Colony Count, Microbial; Disease Models, Animal; Doripenem; Humans; Imipenem; Lung; Meropenem; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Thienamycins; Treatment Outcome | 2012 |
Cefoxitin as an alternative to carbapenems in a murine model of urinary tract infection due to Escherichia coli harboring CTX-M-15-type extended-spectrum β-lactamase.
Topics: Animals; Anti-Bacterial Agents; Bacterial Load; beta-Lactamases; beta-Lactams; Carbapenems; Cefoxitin; Ceftriaxone; Conjugation, Genetic; Disease Models, Animal; Drug Administration Schedule; Ertapenem; Escherichia coli; Escherichia coli Infections; Female; Humans; Imipenem; Kidney; Mice; Microbial Sensitivity Tests; Mutation Rate; Plasmids; Urinary Bladder; Urinary Tract Infections | 2012 |
In vivo pharmacokinetics/pharmacodynamics of colistin and imipenem in Pseudomonas aeruginosa biofilm infection.
Topics: Alginates; Animals; Anti-Bacterial Agents; Area Under Curve; Biofilms; Cells, Immobilized; Colistin; Disease Models, Animal; Female; Glucuronic Acid; Hexuronic Acids; Humans; Imipenem; Lung; Microbial Sensitivity Tests; Plankton; Pseudomonas aeruginosa; Pseudomonas Infections | 2012 |
Restoring methicillin-resistant Staphylococcus aureus susceptibility to β-lactam antibiotics.
Topics: Animals; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactams; Cell Division; Crystallography, X-Ray; Cytoskeletal Proteins; Disease Models, Animal; Drug Resistance, Bacterial; Drug Synergism; Gene Regulatory Networks; Guanosine Diphosphate; Imipenem; Methicillin-Resistant Staphylococcus aureus; Mice; Microbial Sensitivity Tests; Mutation; Protein Structure, Secondary; Protein Transport; Pyridines; Staphylococcal Infections; Thiazoles; Virulence | 2012 |
Fosfomycin-daptomycin and other fosfomycin combinations as alternative therapies in experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.
Topics: Animals; Anti-Bacterial Agents; Colony Count, Microbial; Daptomycin; Disease Models, Animal; Drug Combinations; Drug Resistance, Bacterial; Foreign-Body Reaction; Fosfomycin; Imipenem; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Rats; Rats, Wistar; Rifampin; Staphylococcal Infections | 2013 |
Efficacies of calcium-EDTA in combination with imipenem in a murine model of sepsis caused by Escherichia coli with NDM-1 β-lactamase.
Topics: Animals; Anti-Bacterial Agents; Bacterial Load; beta-Lactam Resistance; beta-Lactamases; Colony Count, Microbial; Disease Models, Animal; Edetic Acid; Escherichia coli; Escherichia coli Infections; Imipenem; Mice; Microbial Sensitivity Tests; Sepsis | 2013 |
Cationic peptides combined with betalactams reduce mortality from peritonitis in experimental rat model.
Topics: Amoxicillin-Potassium Clavulanate Combination; Animals; Anti-Bacterial Agents; Antimicrobial Cationic Peptides; Colistin; Colony Count, Microbial; Disease Models, Animal; Drug Therapy, Combination; Endotoxins; Exudates and Transudates; Imipenem; Male; Peritonitis; Proteins; Rats; Rats, Wistar; Sepsis; Tumor Necrosis Factor-alpha | 2002 |
Antibiotics improve survival and alter the inflammatory profile in a murine model of sepsis from Pseudomonas aeruginosa pneumonia.
Topics: Animals; Anti-Bacterial Agents; Biomarkers; Cytokines; Disease Models, Animal; Gentamicins; Imipenem; Interleukin-6; Lipopolysaccharides; Mice; Mice, Inbred Strains; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Sepsis; Survival Analysis; Time Factors | 2003 |
Intravenous treatment of experimental Staphylococcus aureus endophthalmitis: imipenem versus the combination of ceftazidime and amikacin.
Topics: Amikacin; Animals; Ceftazidime; Colony Count, Microbial; Disease Models, Animal; Drug Therapy, Combination; Endophthalmitis; Eye Infections, Bacterial; Imipenem; Injections, Intravenous; Rabbits; Staphylococcal Infections; Staphylococcus aureus; Vitreous Body | 2003 |
Antibiotic treatment in a murine model of sepsis: impact on cytokines and endotoxin release.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Cecum; Ciprofloxacin; Clindamycin; Colony-Forming Units Assay; Cytokines; Disease Models, Animal; Endotoxins; Enzyme-Linked Immunosorbent Assay; Female; Gram-Negative Bacteria; Imipenem; Inflammation; Interleukin-10; Interleukin-6; Leukocytes; Lipopolysaccharides; Male; Mice; Sepsis; Time Factors; Tumor Necrosis Factor-alpha | 2004 |
Intravitreal vancomycin and amikacin versus intravenous imipenem in the treatment of experimental Staphylococcus aureus endophthalmitis.
Topics: Amikacin; Animals; Disease Models, Animal; Drug Therapy, Combination; Endophthalmitis; Eye Infections, Bacterial; Imipenem; Injections, Intravenous; Rabbits; Staphylococcal Infections; Staphylococcus aureus; Vancomycin; Vitreous Body | 2004 |
The effects of phenytoin and phenobarbital on seizures induced by imipenem/cilastatin in rats.
Topics: Animals; Anticonvulsants; Cilastatin; Disease Models, Animal; Dose-Response Relationship, Drug; Electroencephalography; Epilepsy; Imipenem; Injections, Intraventricular; Male; Phenobarbital; Phenytoin; Prohibitins; Rats; Rats, Wistar; Seizures | 2004 |
Potential therapeutic role of histatin derivative P-113d in experimental rat models of Pseudomonas aeruginosa sepsis.
Topics: Abdominal Cavity; Animals; Antimicrobial Cationic Peptides; Disease Models, Animal; Endotoxins; Histatins; Imipenem; Male; Microbial Sensitivity Tests; Plasma; Polymyxins; Pseudomonas aeruginosa; Pseudomonas Infections; Rats; Rats, Wistar; Salivary Proteins and Peptides; Sepsis; Survival Analysis; Tumor Necrosis Factor-alpha | 2004 |
Comparison of in vivo intrinsic activity of cefepime and imipenem in a Pseudomonas aeruginosa rabbit endocarditis model: effect of combination with tobramycin simulating human serum pharmacokinetics.
Topics: Animals; Anti-Bacterial Agents; Cefepime; Cephalosporins; Disease Models, Animal; Drug Therapy, Combination; Endocarditis, Bacterial; Female; Humans; Imipenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Tobramycin | 2004 |
RNAIII-inhibiting peptide improves efficacy of clinically used antibiotics in a murine model of staphylococcal sepsis.
Topics: Animals; Anti-Bacterial Agents; Bacteremia; Cefazolin; Colony Count, Microbial; Disease Models, Animal; Drug Synergism; Imipenem; Male; Mice; Mice, Inbred BALB C; Oligopeptides; Random Allocation; Sensitivity and Specificity; Sepsis; Staphylococcal Infections; Staphylococcus aureus; Time Factors; Vancomycin | 2005 |
Pharmacokinetic/pharmacodynamic assessment of the in-vivo efficacy of imipenem alone or in combination with amikacin for the treatment of experimental multiresistant Acinetobacter baumannii pneumonia.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Amikacin; Animals; Anti-Bacterial Agents; Disease Models, Animal; Drug Resistance, Multiple, Bacterial; Drug Synergism; Drug Therapy, Combination; Female; Guinea Pigs; Imipenem; Lung; Microbial Sensitivity Tests; Pneumonia, Bacterial | 2005 |
Imipenem for treatment of tuberculosis in mice and humans.
Topics: Animals; Anti-Bacterial Agents; Colony Count, Microbial; Disease Models, Animal; Drug Resistance, Multiple, Bacterial; Female; Humans; Imipenem; Isoniazid; Mice; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Sputum; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2005 |
Efficacy of cefepime and imipenem in experimental murine pneumonia caused by porin-deficient Klebsiella pneumoniae producing CMY-2 beta-Lactamase.
Topics: Animals; Anti-Bacterial Agents; beta-Lactamases; Cefepime; Cephalosporins; Disease Models, Animal; Female; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests; Pneumonia, Bacterial; Porins; Treatment Outcome | 2005 |
Temporin A alone and in combination with imipenem reduces lethality in a mouse model of staphylococcal sepsis.
Topics: Animals; Anti-Bacterial Agents; Antimicrobial Cationic Peptides; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Therapy, Combination; Imipenem; Male; Mice; Mice, Inbred BALB C; Proteins; Sepsis; Staphylococcal Infections; Staphylococcus aureus; Treatment Outcome | 2005 |
The influence of G-CSF addition to antibiotic treatment of experimental sepsis on pulmonary tissue.
Topics: Animals; Anti-Bacterial Agents; Disease Models, Animal; Drug Therapy, Combination; Granulocyte Colony-Stimulating Factor; Imipenem; Leukocyte Count; Lung Diseases; Neutrophils; Pseudomonas Infections; Rats; Rats, Sprague-Dawley; Sepsis; Survival Analysis; Treatment Outcome | 2005 |
Use of bacteriophage in the treatment of experimental animal bacteremia from imipenem-resistant Pseudomonas aeruginosa.
Topics: Animals; Bacteremia; Bacteriophages; Disease Models, Animal; Drug Resistance, Bacterial; Female; Genetic Therapy; Imipenem; Mice; Mice, Inbred BALB C; Microscopy, Electron; Pseudomonas aeruginosa; Temperature | 2006 |
LL-37 protects rats against lethal sepsis caused by gram-negative bacteria.
Topics: Animals; Anti-Bacterial Agents; Antimicrobial Cationic Peptides; Cathelicidins; Cecum; Disease Models, Animal; Endotoxins; Escherichia coli; Escherichia coli Infections; Gram-Negative Bacteria; Imipenem; Injections, Intraperitoneal; Male; Nitrites; Piperacillin; Polymyxin B; Random Allocation; Rats; Rats, Wistar; Serotyping; Shock, Septic; Tumor Necrosis Factor-alpha | 2006 |
Efficacy of antibodies against the N-terminal of Pseudomonas aeruginosa flagellin for treating infections in a murine burn wound model.
Topics: Animals; Anti-Bacterial Agents; Burns; Disease Models, Animal; Female; Flagellin; Imipenem; Immunoglobulin G; Immunotherapy; Mice; Mice, Inbred C57BL; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Wound Healing; Wound Infection | 2006 |
Interaction of antimicrobial peptide temporin L with lipopolysaccharide in vitro and in experimental rat models of septic shock caused by gram-negative bacteria.
Topics: Animals; Anti-Infective Agents; Antimicrobial Cationic Peptides; beta-Lactams; Disease Models, Animal; Drug Therapy, Combination; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; Lipopolysaccharides; Male; Microbial Sensitivity Tests; Peritonitis; Piperacillin; Proteins; Rats; Rats, Wistar; Shock, Septic | 2006 |
Prevention of rifampicin resistance in Acinetobacter baumannii in an experimental pneumonia murine model, using rifampicin associated with imipenem or sulbactam.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Animals; Anti-Bacterial Agents; Disease Models, Animal; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Female; Imipenem; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests; Mutation; Pneumonia, Bacterial; Rifampin; Sulbactam | 2006 |
[Comparative study of treatment with quinupristin-dalfopristin alone or in combination with gentamicin, teicoplanin, imipenem or levofloxacin in experimental endocarditis due to a multidrug-resistant Enterococcus faecium].
Topics: Aged; Animals; Anti-Bacterial Agents; Disease Models, Animal; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Endocarditis, Bacterial; Enterococcus faecium; Female; Gentamicins; Gram-Positive Bacterial Infections; Humans; Imipenem; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Rabbits; Teicoplanin; Virginiamycin | 2006 |
Effect of early and late antibiotic treatment in experimental acute pancreatitis in rats.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Cholagogues and Choleretics; Ciprofloxacin; Disease Models, Animal; Drug Therapy, Combination; Imipenem; Intestines; Male; Metronidazole; Pancreatitis, Acute Necrotizing; Random Allocation; Rats; Rats, Wistar; Taurocholic Acid; Time Factors | 2007 |
Pharmacokinetic-pharmacodynamic modeling and simulation for in vivo bactericidal effect in murine infection model.
Topics: Animals; Anti-Bacterial Agents; Area Under Curve; Bacterial Infections; Carbapenems; Cilastatin; Disease Models, Animal; Doripenem; Female; Imipenem; Meropenem; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Models, Biological; Thienamycins | 2008 |
Effects of intravitreal corticosteroid in the treatment of Staphylococcus aureus-induced experimental endophthalmitis.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Dexamethasone; Disease Models, Animal; Drug Therapy, Combination; Electroretinography; Endophthalmitis; Eye Infections, Bacterial; Female; Glucocorticoids; Imipenem; Injections; Rabbits; Staphylococcal Infections; Staphylococcus aureus; Vancomycin; Vitreous Body | 2008 |
Alpha-MSH promotes spontaneous post-ischemic pneumonia in mice via melanocortin-receptor-1.
Topics: Agouti Signaling Protein; alpha-MSH; Animals; Anti-Bacterial Agents; B-Lymphocytes; Bronchoalveolar Lavage Fluid; Cytokines; Disease Models, Animal; Imipenem; Infarction, Middle Cerebral Artery; Lung; Macrophages; Male; Mice; Mice, Inbred C57BL; Pneumonia; Radioimmunoassay; Receptor, Melanocortin, Type 1; Spleen; T-Lymphocytes; Up-Regulation | 2008 |
Pharmacokinetic and pharmacodynamic properties of biapenem, a carbapenem antibiotic, in rat experimental model of severe acute pancreatitis.
Topics: Acute Disease; Animals; Anti-Bacterial Agents; Ascites; Bacterial Infections; Disease Models, Animal; Dose-Response Relationship, Drug; Imipenem; Injections, Subcutaneous; Intestines; Lymph Nodes; Male; Pancreas; Pancreatitis; Rats; Rats, Wistar; Severity of Illness Index; Taurocholic Acid; Thienamycins | 2008 |
Imipenem in Legionnaires' disease.
Topics: Animals; Cilastatin; Cyclopropanes; Disease Models, Animal; Drug Evaluation; Drug Therapy, Combination; Guinea Pigs; Imipenem; Legionnaires' Disease; Thienamycins | 1984 |
Therapeutic efficacy of a polymyxin B-dextran 70 conjugate in experimental model of endotoxemia.
Topics: Animals; Bacteremia; Dextrans; Disease Models, Animal; Drug Carriers; Endotoxins; Escherichia coli Infections; Female; Galactosamine; Imipenem; Lipopolysaccharides; Mice; Polymyxin B; Toxemia | 1995 |
Biapenem versus imipenem in the treatment of experimental intraabdominal infections.
Topics: Abdomen; Animals; Bacteria; Bacterial Infections; Disease Models, Animal; Imipenem; Male; Microbial Sensitivity Tests; Rats; Rats, Sprague-Dawley; Thienamycins | 1995 |
Pathogenesis and prevention of early pancreatic infection in experimental acute necrotizing pancreatitis.
Topics: Acute Disease; Administration, Oral; Amphotericin B; Animals; Bacteria; Bacterial Infections; Bacterial Physiological Phenomena; Cecal Diseases; Cefotaxime; Colistin; Disease Models, Animal; Drug Therapy, Combination; Imipenem; Injections, Intravenous; Kidney Diseases; Male; Necrosis; Pancreas; Pancreatic Diseases; Pancreatitis; Rats; Rats, Sprague-Dawley; Survival Rate; Tobramycin | 1995 |
Differential antibiotic-induced release of endotoxin from gram-negative bacteria.
Topics: Animals; Ceftazidime; Disease Models, Animal; Escherichia coli; Escherichia coli Infections; Female; Galactosamine; Imipenem; Lipid A; Lipopolysaccharides; Mice; Microbial Sensitivity Tests | 1994 |
Treatment with imipenem of experimental endocarditis caused by penicillin-resistant Streptococcus sanguis.
Topics: Animals; Disease Models, Animal; Drug Therapy, Combination; Endocarditis, Bacterial; Gentamicins; Imipenem; Microbial Sensitivity Tests; Penicillin Resistance; Rabbits; Streptococcal Infections; Streptococcus sanguis | 1994 |
Efficacy of a novel injectable cephalosporin, Cefclidin, on the experimental complicated urinary tract infections with urinary stones caused by Pseudomonas aeruginosa and Proteus mirabilis.
Topics: Animals; Cephalosporins; Disease Models, Animal; Drug Resistance, Microbial; Female; Imipenem; Kidney Calculi; Proteus Infections; Proteus mirabilis; Pseudomonas Infections; Rats; Rats, Sprague-Dawley; Urinary Bladder Calculi; Urinary Calculi; Urinary Tract Infections | 1994 |
Investigation of the potential role of Enterococcus faecalis in the pathophysiology of experimental peritonitis.
Topics: Abscess; Amoxicillin; Animals; Anti-Bacterial Agents; Bacteremia; Bacteroides fragilis; Bacteroides Infections; Body Weight; Disease Models, Animal; Drug Synergism; Enterococcus faecalis; Escherichia coli; Escherichia coli Infections; Gentamicins; Gram-Positive Bacterial Infections; Imipenem; Male; Microbial Sensitivity Tests; Ornidazole; Pefloxacin; Peritoneum; Peritonitis; Rats; Rats, Sprague-Dawley; Specific Pathogen-Free Organisms | 1994 |
Evaluation of antimicrobials combined with hyperbaric oxygen in a mouse model of clostridial myonecrosis.
Topics: Animals; Clindamycin; Combined Modality Therapy; Disease Models, Animal; Female; Gas Gangrene; Hyperbaric Oxygenation; Imipenem; Injections, Intraperitoneal; Metronidazole; Mice; Mice, Inbred Strains; Necrosis; Penicillins; Survival Rate; Time Factors | 1994 |
Synergic activity of imipenem/cilastatin combined with cefotiam against methicillin-resistant Staphylococcus aureus.
Topics: Animals; Cefotiam; Cilastatin; Disease Models, Animal; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Imipenem; Kinetics; Male; Methicillin Resistance; Mice; Mice, Inbred ICR; Staphylococcal Infections; Staphylococcus aureus | 1993 |
Impact of different classes antimicrobial agents on plasma endotoxin activity.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Bacteremia; Blood Pressure; Cefotaxime; Cephalosporins; Ciprofloxacin; Colony Count, Microbial; Disease Models, Animal; Endotoxins; Escherichia coli; Escherichia coli Infections; Gentamicins; Imipenem; Male; Peritoneal Diseases; Peritoneum; Rats; Rats, Wistar; Thienamycins | 1996 |
Noncompromised penicillin-resistant pneumococcal pneumonia CBA/J mouse model and comparative efficacies of antibiotics in this model.
Topics: Animals; Anti-Bacterial Agents; Cefotaxime; Disease Models, Animal; Imipenem; Lung; Male; Mice; Mice, Inbred CBA; Mice, Inbred ICR; Microbial Sensitivity Tests; Penicillin G; Penicillin Resistance; Pneumonia, Pneumococcal; Species Specificity; Streptococcus pneumoniae; Vancomycin | 1996 |
Experimental posttraumatic Bacillus cereus endophthalmitis in a swine model. Efficacy of intravitreal ciprofloxacin, vancomycin, and imipenem.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Bacillaceae Infections; Bacillus cereus; Ciprofloxacin; Disease Models, Animal; Endophthalmitis; Eye Diseases; Eye Infections, Bacterial; Eye Injuries, Penetrating; Imipenem; Pilot Projects; Random Allocation; Retinitis; Swine; Thienamycins; Vancomycin; Vitreous Body | 1996 |
Experimental pseudomonal posttraumatic endophthalmitis in a swine model. Treatment with ceftazidime, amikacin, and imipenem.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Disease Models, Animal; Endophthalmitis; Eye Infections, Bacterial; Eye Injuries, Penetrating; Follow-Up Studies; Imipenem; Injections; Pseudomonas aeruginosa; Pseudomonas Infections; Sclera; Swine; Thienamycins; Vitreous Body | 1997 |
Therapeutic efficacy of intravitreal ceftazidime, imipenem, and amikacin in a swine model of posttraumatic Pseudomonas aeruginosa endophthalmitis.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Disease Models, Animal; Endophthalmitis; Eye Infections, Bacterial; Eye Injuries, Penetrating; Imipenem; Pseudomonas Infections; Swine; Vitreous Body | 1997 |
Predictive value of several signs of infection as surrogate markers for mortality in a neutropenic guinea pig model of Pseudomonas aeruginosa sepsis.
Topics: Animals; Anti-Bacterial Agents; Biomarkers; Ceftazidime; Cephalosporins; Diarrhea; Disease Models, Animal; Female; Guinea Pigs; Imipenem; Meropenem; Movement Disorders; Neutropenia; Predictive Value of Tests; Pseudomonas Infections; Regression Analysis; Respiration; Thienamycins; Time Factors; Tobramycin; Weight Loss | 1997 |
Comparative therapeutic efficacy of clinafloxacin in a Pseudomonas aeruginosa mouse renal abscess model.
Topics: Abscess; Animals; Anti-Infective Agents; Area Under Curve; Ceftazidime; Cilastatin; Cilastatin, Imipenem Drug Combination; Ciprofloxacin; Colony Count, Microbial; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy, Combination; Female; Fluoroquinolones; Half-Life; Imipenem; Kidney; Kidney Diseases; Mice; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolones; Treatment Outcome | 1998 |
Multiple roles for IL-12 in a model of acute septic peritonitis.
Topics: Acute Disease; Animals; Cecal Diseases; Cilastatin; Cilastatin, Imipenem Drug Combination; Disease Models, Animal; Drug Combinations; Drug Therapy, Combination; Female; Fibrosis; Imipenem; Immune Sera; Immunization, Passive; Interferon-gamma; Interleukin-10; Interleukin-12; Intestinal Perforation; Ligation; Mice; Peritoneum; Peritonitis; Sepsis; Wound Healing | 1999 |
Treatment of experimental pneumonia in rats caused by a PER-1 extended-spectrum beta-lactamase-producing strain of Pseudomonas aeruginosa.
Topics: Amikacin; Animals; Anti-Bacterial Agents; beta-Lactamases; Cefepime; Cephalosporins; Colony Count, Microbial; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Imipenem; Lung; Male; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Rats; Rats, Wistar | 1999 |
Effects of antibiotic therapy on Pseudomonas aeruginosa-induced lung injury in a rat model.
Topics: Animals; Aztreonam; Cilastatin; Cilastatin, Imipenem Drug Combination; Disease Models, Animal; Drug Combinations; Drug Therapy, Combination; Imipenem; Lung Diseases; Male; Microbial Sensitivity Tests; Monobactams; Pseudomonas aeruginosa; Pseudomonas Infections; Rats; Rats, Sprague-Dawley | 1999 |
Comparison between MRI, microbiology and histology in evaluation of antibiotics in a murine model of thigh infection.
Topics: Animals; Anti-Bacterial Agents; Bacteriological Techniques; Cilastatin; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Therapy, Combination; Evaluation Studies as Topic; Extremities; Histological Techniques; Imipenem; Magnetic Resonance Imaging; Male; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Staphylococcal Infections; Staphylococcus aureus; Vancomycin | 1999 |
Therapeutic efficacy of continuous arterial infusion of an antibiotic and a protease inhibitor via the superior mesenteric artery for acute pancreatitis in an animal model.
Topics: Acute Disease; Amylases; Animals; Anti-Bacterial Agents; Bacterial Infections; Bacterial Translocation; Benzamidines; Bile; Disease Models, Animal; Dogs; Female; Guanidines; Imipenem; Infusions, Intra-Arterial; Intestinal Mucosa; Male; Mesenteric Artery, Superior; Microscopy, Electron, Scanning; Pancreas; Pancreatitis; Peroxidase; Protease Inhibitors; Thienamycins | 2000 |
In vivo activity of levofloxacin alone or in combination with imipenem or amikacin in a mouse model of Acinetobacter baumannii pneumonia.
Topics: Acinetobacter Infections; Amikacin; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Area Under Curve; Disease Models, Animal; Drug Therapy, Combination; Female; Imipenem; Levofloxacin; Mice; Mice, Inbred C3H; Microbial Sensitivity Tests; Ofloxacin; Pneumonia, Bacterial; Thienamycins | 2000 |
Sulbactam efficacy in experimental models caused by susceptible and intermediate Acinetobacter baumannii strains.
Topics: Acinetobacter; Acinetobacter Infections; Animals; Anti-Bacterial Agents; Disease Models, Animal; Endocarditis; Heart Valves; Imipenem; Lung; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests; Pneumonia; Rabbits; Sulbactam; Survival Rate; Time Factors | 2001 |
[In vitro and in vivo activities of panipenem against penicillin-resistant Streptococcus pneumoniae].
Topics: Ampicillin; Animals; beta-Alanine; Cefozopran; Ceftriaxone; Cephalosporins; Cilastatin; Cilastatin, Imipenem Drug Combination; Disease Models, Animal; Drug Combinations; Drug Resistance; Imipenem; Male; Meropenem; Mice; Mice, Inbred Strains; Penicillin Resistance; Pneumonia, Pneumococcal; Streptococcus pneumoniae; Thienamycins; Vancomycin | 2001 |
A combination of roxithromycin and imipenem as an antimicrobial strategy against biofilms formed by Staphylococcus aureus.
Topics: Animals; Anti-Bacterial Agents; Biofilms; Disease Models, Animal; Drug Therapy, Combination; Humans; Imipenem; Mice; Roxithromycin; Staphylococcal Skin Infections; Staphylococcus aureus; Thienamycins; Treatment Outcome | 2001 |
Therapeutic efficacy of the polymyxin-like peptide ranalexin in an experimental model of endotoxemia.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Disease Models, Animal; Endotoxemia; Escherichia coli Infections; Imipenem; Male; Peptides, Cyclic; Polymyxin B; Polymyxins; Rats; Survival Rate; Thienamycins; Tumor Necrosis Factor-alpha | 2001 |
Effects of parenterally administered ciprofloxacin in a murine model of pulmonary Pseudomonas aeruginosa infection mimicking ventilator-associated pneumonia.
Topics: Animals; Anti-Infective Agents; Area Under Curve; Cefozopran; Cephalosporins; Cilastatin; Ciprofloxacin; Disease Models, Animal; Imipenem; Infusions, Parenteral; Male; Mice; Pneumonia, Bacterial; Protease Inhibitors; Pseudomonas aeruginosa; Pseudomonas Infections; Respiration, Artificial; Thienamycins | 2001 |
[The effect of antibiotic therapy on lung pathology in experimental models of sepsis].
Topics: Animals; Bacteroides fragilis; Disease Models, Animal; Escherichia coli; Gram-Negative Bacterial Infections; Imipenem; Lung Diseases; Prognosis; Rats; Rats, Wistar; Sepsis; Thienamycins | 2002 |
Inhibition of nitric oxide synthesis improves survival in a murine peritonitis model of sepsis that is not cured by antibiotics alone.
Topics: Amino Acid Oxidoreductases; Animals; Arginine; Cilastatin; Cilastatin, Imipenem Drug Combination; Disease Models, Animal; Drug Combinations; Drug Therapy, Combination; Escherichia coli Infections; Imipenem; Male; Mice; Nitric Oxide Synthase; omega-N-Methylarginine; Peritonitis | 1992 |
[Resistance to antibiotic treatment produced in a model of experimental Pseudomonas aeruginosa peritonitis].
Topics: Amikacin; Animals; Ceftazidime; Ciprofloxacin; Disease Models, Animal; Drug Resistance, Microbial; Drug Therapy, Combination; Imipenem; Mice; Peritonitis; Pseudomonas aeruginosa; Pseudomonas Infections | 1992 |
Binding affinity for penicillin-binding protein 2a correlates with in vivo activity of beta-lactam antibiotics against methicillin-resistant Staphylococcus aureus.
Topics: Acyltransferases; Ampicillin; Animals; Anti-Bacterial Agents; Bacterial Proteins; Carrier Proteins; Disease Models, Animal; Endocarditis, Bacterial; Hexosyltransferases; Imipenem; Methicillin; Multienzyme Complexes; Muramoylpentapeptide Carboxypeptidase; Nafcillin; Penicillin Resistance; Penicillin-Binding Proteins; Peptidyl Transferases; Rabbits; Staphylococcal Infections; Staphylococcus aureus; Ticarcillin | 1990 |
Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models.
Topics: Animals; Anti-Bacterial Agents; Cefazolin; Ceftazidime; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gentamicins; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Lung; Mice; Mice, Inbred ICR; Muscles; Pneumonia | 1989 |
In vitro susceptibility and in vivo efficacy of antimicrobials in the treatment of Bacteroides fragilis-Escherichia coli infection in mice.
Topics: Abscess; Ampicillin; Animals; Anti-Bacterial Agents; Bacteroides fragilis; Bacteroides Infections; Cefamandole; Cefotetan; Cefoxitin; Ceftizoxime; Cilastatin; Cilastatin, Imipenem Drug Combination; Disease Models, Animal; Drug Combinations; Drug Therapy, Combination; Escherichia coli; Escherichia coli Infections; Imipenem; Male; Mice; Skin Diseases; Sulbactam | 1989 |
Chemotherapy of experimental (murine) Clostridium perfringens type A gas gangrene.
Topics: Animals; Ciprofloxacin; Clindamycin; Clostridium perfringens; Disease Models, Animal; Gas Gangrene; Imipenem; Mice; Microbial Sensitivity Tests; Penicillin G; Rifampin | 1988 |
Absence of a postantibiotic effect in experimental Pseudomonas endocarditis treated with imipenem, with or without gentamicin.
Topics: Animals; Aortic Valve; Disease Models, Animal; Drug Therapy, Combination; Endocarditis, Bacterial; Gentamicins; Heart Valve Diseases; Humans; Imipenem; Pseudomonas aeruginosa; Pseudomonas Infections; Rats; Rats, Inbred Strains; Thienamycins; Tricuspid Valve | 1988 |
Animal model for evaluating the convulsive liability of beta-lactam antibiotics.
Topics: Animals; Anti-Bacterial Agents; beta-Lactams; Binding, Competitive; Cefazolin; Cilastatin; Cilastatin, Imipenem Drug Combination; Cyclopropanes; Disease Models, Animal; Drug Combinations; gamma-Aminobutyric Acid; Imipenem; Lactams; Male; Mice; Pentylenetetrazole; Seizures; Thienamycins | 1988 |